In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
| Professional Services Industry | Industrials Sector | August James Troendle CEO | XDUS Exchange | US58506Q1094 ISIN |
| US Country | 6,500 Employees | - Last Dividend | - Last Split | 11 Aug 2016 IPO Date |
Medpace Holdings, Inc., founded in 1992 and headquartered in Cincinnati, Ohio, is a key player in the provision of comprehensive clinical research services for the development of drugs and medical devices. Spanning its operations across North America, Europe, and Asia, the company supports pharmaceutical, biotechnology, and medical device industries through the entire clinical development process, from Phase I to Phase IV, across a wide range of therapeutic areas. Its aim is to facilitate the journey of bringing new and innovative treatments to market efficiently and effectively.